Can I Import Peptides for Resale?

You can build a resale business around research peptides without importing anything yourself, and for most buyers that is the sounder structure. Importing directly makes your business the importer of record — you own the customs classification, the entry documentation, the product paperwork, and every question a regulator, a payment processor, or a customer asks about that shipment months later. Buying through a domestic wholesale account moves that burden upstream to a supplier who already carries it. Whether your specific business may import a specific compound, under what classification, and with what documentation is a question for a licensed customs broker and your own attorney. What follows is informational and is not legal advice.

What being the importer of record actually signs you up for

The phrase sounds administrative. It isn't. When your entity is named on the entry, your entity is the party that answers for the accuracy of the declared classification and valuation, for the description of the goods, and for whether the shipment was eligible to enter at all. If the paperwork is wrong, the manufacturer on the other side of the world is not the one holding the file.

That responsibility does not end at the port. It follows the inventory. If a customer, a processor, or an auditor later asks what the product is, where it came from, and what testing supports the label, you need documentation you can produce on demand — not an email thread with a sales rep. Research-use-only compounds are documentation-heavy by nature, and a thin paper trail is the single most common reason a small importer ends up unable to defend inventory it already paid for.

There is also the practical layer that nobody puts in the pitch deck. Cross-border shipments sit in transit, then they sit in clearance. Lead times are not a number you can plan a launch around; holds happen for reasons that have nothing to do with your compound and everything to do with paperwork, brokerage backlog, or a flagged shipper. Cold-chain and handling exposure stretches across that whole window. And if a batch arrives out of specification, your recourse is a dispute with a manufacturer in another legal system, denominated in a currency you don't control, with an arbitration clause you probably didn't negotiate.

The questions to put in front of counsel before anything ships

Do not treat any of the following as settled. Treat them as the agenda for a conversation with an attorney who knows import and product regulation, and with your state board if you operate a licensed facility.

How is this compound classified for entry purposes, and who decides? Classification drives duty, documentation, and eligibility. Ask your broker to put the classification in writing and ask counsel whether the classification is defensible.

What does research-use-only labeling actually do, and what does it not do? It is a scope statement about the intended use of the material. Ask counsel what obligations attach to it in your jurisdiction, what your labeling and record-keeping duties are, and where the line sits between selling a research material and something else entirely.

Who in my downstream chain is regulated, and does that change my obligations? A reseller shipping to research customers, a clinic, and a telehealth entity are three different fact patterns. Ask which one describes you.

What am I representing when I resell? If you put your brand on someone else's material, you may be taking on representations about identity and purity. Ask counsel what your exposure looks like and what supplier documentation you need to hold.

Do my payment processor, insurer, and landlord know what I stock? Contractual restrictions are often stricter than anything a regulator has said, and they are the ones that shut businesses down fastest.

If any part of your catalog is being positioned toward veterinary channels, that is a separate regulatory track with its own rules and its own labeling expectations — talk to a veterinarian as well as your attorney before assuming research-use framing carries over. And to be plain about it: no article can tell you that your state permits or forbids a given activity. Get that answer from your counsel and your board, in writing.

Direct import versus a domestic wholesale account

The decision is usually not about price per vial. It is about who absorbs risk, who holds documentation, and how much working capital gets locked into a container you cannot inspect.

Margins on imported material can look better on a spreadsheet. What the spreadsheet rarely models is the cost of independent verification, the freight and brokerage variability, the capital sitting idle in transit, and the batch you cannot sell because the documentation does not hold up. Actual landed economics vary widely by volume, compound category, and how much testing you commission — which is exactly why a precise margin figure from anyone who has not seen your numbers should be ignored.

Documentation is the whole game

Whatever sourcing route you choose, the certificate of analysis is the asset. A COA that means something identifies the specific batch, states the analytical method used, reports purity, and comes from testing that you can actually confirm happened. A COA that means nothing is a PDF with a logo, no batch number, and no way to trace it back to the lab.

High-performance liquid chromatography is the standard purity method for peptides, and the chromatogram is the part worth reading — a purity percentage with no trace behind it is an assertion, not a result. Beyond identity and purity, a serious testing panel looks at the contamination categories that matter for material handled in a lab setting, including endotoxin, heavy metals, residual solvents, and microbial load. Ask any supplier which panels run on every batch versus which run occasionally, and ask whether the results are published or produced on request.

Three industry practices should make you slow down. First, pricing that only appears after a sales call — opacity at the quoting stage rarely improves after you sign. Second, COAs sold as an add-on, or released only to accounts above a certain size; testing documentation is part of the product, not an upsell. Third, testing you cannot independently confirm: an unnamed lab, an undated report, or a batch number that doesn't match the vial in your hand.

How to vet a supplier before you commit inventory

Start with the boring operational questions, because those are the ones that determine whether you can actually run a business on this relationship. Does the supplier publish wholesale pricing tiers, or do you have to negotiate blind? Is there a stated minimum, and does it scale in a way that matches how you actually reorder? Is fulfillment domestic, and is the lead time something they will state plainly?

Then test the documentation. Pick a compound, ask for the COA on the current batch, and check whether the batch number on the paperwork matches what arrives. Ask whether the COA is publicly posted or gated. Ask what happens when a batch fails internal specification — a supplier with a real quality system will describe a process; one without will describe how rare failures are.

Finally, look at catalog depth and consistency. A supplier who can hold identity and purity across a broad range of compounds — from widely stocked items like BPC-157 and GHK-Cu through narrower categories such as growth factor and tissue signaling research or mitochondrial and metabolic pathway research — is demonstrating process control, not just inventory. Research into these compounds is ongoing and preliminary in most categories; studies indicate mechanisms of interest, and honest suppliers describe the science that way rather than promising outcomes.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built for businesses that would rather buy documented domestic inventory than become an importer. Every compound is tested to 99%+ HPLC purity, and every batch runs through a 7-panel test rather than a spot check on selected lots. Those results are published as verifiable COAs — a prospective partner can look up the lab results before placing an order, without asking a rep for permission and without paying for the document.

Fulfillment is domestic, with orders shipping in five to seven days, which means reorder planning is a supply-chain question rather than a customs question. Wholesale pricing tiers are presented to applicants rather than negotiated in the dark. Onboarding runs as a 3-step wholesale application: submit business details, get reviewed for program fit, and receive tier pricing and account access.

All compounds are supplied for research use only. They are not FDA-approved drugs, they are not sold for human consumption, and nothing in the catalog should be described to your own customers as a therapy. Real Peptides does not supply semaglutide, tirzepatide, retatrutide, or Melanotan II under any program, and supplies are never bundled with compounds.

Where this leaves a serious buyer

If you have counsel telling you your import structure is clean, your broker lined up, and capital you're comfortable parking in transit, direct import is a legitimate path. If what you actually want is documented material, predictable domestic lead times, and COAs you can hand to anyone who asks, a wholesale account gets you there without adding a customs function to your business. Confirm your own licensing and resale position with your attorney and your state board first — then apply, and evaluate the program on the documentation it hands you.

For pricing tiers and program details, see the wholesale peptides program, or apply for a wholesale account to start the review process.